通化金马(000766) - 通化金马投资者关系活动记录表

Group 1: Investor Relations Activities - The company participated in the 2021 Jilin Province online collective performance briefing on May 14, 2021 [1] - The event was held on the "Investor Relations Interactive Platform" provided by Shenzhen Panorama Network Co., Ltd. [1] Group 2: Key Questions and Answers - Question about whether the company's drugs will be included in the medical insurance directory this year; the company is monitoring the situation [1][2] - Inquiry regarding the company's plans for share repurchase; currently, there are no plans for share buyback [1][2] - Question about other new drugs in development besides the Amber Dihydroaminoacridine Tablets; the company has two invested drug research institutions [2] - Inquiry about the resolution of the company's debt issues related to the controlling shareholder's equity pledge dispute, which is currently in judicial proceedings [2] - Question regarding the timeline for the new drug launch; the Amber Dihydroaminoacridine Tablets have completed enrollment of 600 cases, with results expected by July or August 2021 [2]